Compare ESP & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ESP | SGMT |
|---|---|---|
| Founded | 1928 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.6M | 169.4M |
| IPO Year | 1995 | 2021 |
| Metric | ESP | SGMT |
|---|---|---|
| Price | $60.70 | $7.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | ★ $64.00 | $26.13 |
| AVG Volume (30 Days) | 42.1K | ★ 1.4M |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | ★ 1.50% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.74 | N/A |
| Revenue | ★ $43,950,872.00 | $2,000,000.00 |
| Revenue This Year | $10.30 | N/A |
| Revenue Next Year | $10.00 | N/A |
| P/E Ratio | $21.87 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $36.00 | $4.50 |
| 52 Week High | $74.77 | $11.41 |
| Indicator | ESP | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 45.22 | 54.97 |
| Support Level | $52.70 | $7.09 |
| Resistance Level | $61.58 | $7.95 |
| Average True Range (ATR) | 3.67 | 0.45 |
| MACD | -0.50 | 0.03 |
| Stochastic Oscillator | 11.59 | 57.48 |
Espey Manufacturing & Electronics Corp is a power electronics design and OEM manufacturing company delivering products for military and severe environment applications. Its products include power supplies, power converters, filters, power transformers, magnetic components, power distribution equipment, UPS systems, and antennas. The applications of these products include AC and DC locomotives, shipboard power, shipboard radar, airborne power, ground-based radar, and ground mobile power. Espey services include design and development to specification, build to specifications provided by the customer, build to print, design services, design studies, environmental testing services, metal fabrication, painting services, and development of automatic testing equipment.
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.